NCT06564753CompletedPhase 2
Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of NA-931 for Weight Management in Subjects Who Are Obese or Overweight With at Least One Weight-related Comorbid Condition
Source: ClinicalTrials.gov · Last updated 23 May 2025
Brief summary (registry, in English)
This is a Phase 2 randomized, double-blind, placebo-controlled, parallel arm study of NA-931 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 126 (actual)
- First submitted
- 16 Aug 2024
- Start date
- 19 Jul 2024
- Primary completion date
- 27 Feb 2025
- Lead sponsor
- Biomed Industries, Inc.
- Diseases
- Obesity
- NCT number
- NCT06564753
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 126
- From 19 Jul 2024 to the primary completion date, 27 Feb 2025
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any prescription or over-the-counter medications intended for weight loss within 6 months of screening
Other illness
- History of or current clinically significant medical or psychiatric disorder that, in the opinion of the Investigator, does not support study participation
- Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)
Lab values
- Calcitonin ≥20 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)
- Any Glucagon-Like Peptide 1 (GLP-1) receptor agonist or GLP-1/ Glucose-dependent Insulinotropic Polypeptide (GIP) dual agonist within 6 months of Screening
Other
- Self-reported body weight change of 5% or more within 3 months of screening
- Current or past diagnosis of chronic pancreatitis
Who the study is looking for
- Age ≥18 years of age at the time of signing the informed consent
- Body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI <50 kg/m2
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Camperdown | Australia | Unknown status |
| - Coordinator of this site? Confirm its status | Heidelberg Heights | Australia | Unknown status |
| - Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
| - Coordinator of this site? Confirm its status | Merewether | Australia | Unknown status |
| - Coordinator of this site? Confirm its status | St Leonards | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.